Chairperson(s) : TBD (Affiliation, Country)
-
[OP3-1] Residual risk of remnant cholesterol in patients treated to LDL-C goal: a landmark analysis of the RACING trial
Sung Gyun Ahn Yonsei University Wonju College of Medicine, Republic of Korea 08:50~09:00 -
[OP3-2] Lower cardiovascular event risk with bempedoic acid versus ezetimibe in statin-intolerant atherosclerotic cardiovascular disease (ASCVD): a 3,540-patient TriNetX analysis
Ahmed Elaraby Faculty of medicine, Al-Azhar University, Egypt 09:00~09:10 -
[OP3-3] Age-dependent association of atherogenic dyslipidemia with incident cardiovascular disease: a nationwide Korean cohort study
Ye Seul Yang Seoul National University College of Medicine, Republic of Korea 09:10~09:20 -
[OP3-4] Deep learning analysis of BMI, metabolic risk factors, and sex hormones in U.S. women: a NHANES study
Saheed Oladele Amusat Beaumont Hospital, Ireland 09:20~09:30 -
[OP3-5] Prevalence of high inflammatory risk in atherosclerotic cardiovascular disease with and without chronic kidney disease: findings from POSEIDON - a global cross-sectional prevalence study
Kyungsoo Won Novo Nordisk Korea, Republic of Korea 09:30~09:40 -
[OP3-6] Real-world efficacy and tolerability of inclisiran in Malaysian patients with atherosclerotic cardiovascular disease: a single-centre experience
Kim Fong Ng KPJ Kluang Specialist Hospital, Malaysia 09:40~09:50 -
[OP3-7] A Korean multidimensional social determinants of health index identifies individuals at elevated risk of severe coronary artery calcification: evidence from the CMERC cohort
Jooeun Jeon Ewha Womans University Mokdong Hospital, Republic of Korea 09:50~10:00 -
[OP3-8] Efficacy and safety of enlicitide decanoate, an oral macrocyclic peptide inhibitor of PCSK9, compared with bempedoic acid, ezetimibe, or bempedoic acid co-administered with ezetimibe in statin-treated adults with hypercholesterolemia: phase 3 CORALreef AddOn trial
Maria Carolina Emilia Villanueva MSD Philippines, Republic of Korea 10:00~10:10
